QTTB
Q32 Bio Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.79
+3.59%Oct 9, 2026, 13:59 UTC
Q32 Bio Inc. hired José Trevejo as chief medical officer.
Source:Sep 21, 2026, 13:15 UTC
Q32 Bio announced that additional 36-week results and initial 16-week off-drug findings from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata will be presented at the EADV Congress in Vienna, September 30–October 3, 2026.
Source:Aug 5, 2026, 10:59 UTC
Q32 Bio Inc. reported its financial results for the second quarter of 2026, with cash and cash equivalents of $106.3 million as of June 30, 2026.
Source:Jul 13, 2026, 20:01 UTC
Q32 Bio Inc. announced an underwritten public offering of $200 million of its common stock and pre-funded warrants.
Jul 13, 2026, 10:59 UTC
Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata, supporting further development and a planned registration-directed program in the first half of 2027.
Jun 29, 2026, 05:57 UTC
Q32 Bio Inc. was added to the Russell Microcap Index.
Source: